齐齐哈尔医学院学报
齊齊哈爾醫學院學報
제제합이의학원학보
JOURNAL OF QIQIHAR MEDICAL COLLEGE
2015年
7期
958-960
,共3页
王镇南%唐志%李淑慧%詹德超%杨东红
王鎮南%唐誌%李淑慧%詹德超%楊東紅
왕진남%당지%리숙혜%첨덕초%양동홍
晚期子宫内膜癌%新辅助化疗%近期疗效%毒副作用
晚期子宮內膜癌%新輔助化療%近期療效%毒副作用
만기자궁내막암%신보조화료%근기료효%독부작용
Advanced endometrial cancer%Neoadjuvant chemotherapy%Short -term effect%Toxicity
目的:探讨新辅助化疗治疗晚期子宫内膜癌的临床效果。方法80例晚期子宫内膜癌患者随机分为观察组和对照组,各40例。观察组患者给予顺铂+紫杉醇方案的新辅助化疗4个疗程;对照组患者手术后进行相同方案的化疗。结果观察组的化疗总有效率为75.0%,明显高于对照组的52.5%,差异有统计学意义(P<0.05)。观察组的胃肠道反应和骨髓抑制的发生率,以及毒副作用的总发生率,均显著低于对照组( P<0.05)。结论与常规术后化疗比较,新辅助化疗治疗晚期子宫内膜癌的近期疗效显著,且毒副作用发生率较低,但仍需进行大样本的研究进一步明确其价值。
目的:探討新輔助化療治療晚期子宮內膜癌的臨床效果。方法80例晚期子宮內膜癌患者隨機分為觀察組和對照組,各40例。觀察組患者給予順鉑+紫杉醇方案的新輔助化療4箇療程;對照組患者手術後進行相同方案的化療。結果觀察組的化療總有效率為75.0%,明顯高于對照組的52.5%,差異有統計學意義(P<0.05)。觀察組的胃腸道反應和骨髓抑製的髮生率,以及毒副作用的總髮生率,均顯著低于對照組( P<0.05)。結論與常規術後化療比較,新輔助化療治療晚期子宮內膜癌的近期療效顯著,且毒副作用髮生率較低,但仍需進行大樣本的研究進一步明確其價值。
목적:탐토신보조화료치료만기자궁내막암적림상효과。방법80례만기자궁내막암환자수궤분위관찰조화대조조,각40례。관찰조환자급여순박+자삼순방안적신보조화료4개료정;대조조환자수술후진행상동방안적화료。결과관찰조적화료총유효솔위75.0%,명현고우대조조적52.5%,차이유통계학의의(P<0.05)。관찰조적위장도반응화골수억제적발생솔,이급독부작용적총발생솔,균현저저우대조조( P<0.05)。결론여상규술후화료비교,신보조화료치료만기자궁내막암적근기료효현저,차독부작용발생솔교저,단잉수진행대양본적연구진일보명학기개치。
Objective This paper as to investigate the clinical effect of neoadjuvant chemotherapy in the treatmentofadvancedendometrialcancer.Methods 80patientswithadvancedendometrialcancerwererandomly divided into observation group and control group, 40 in each group.Patients in observation group were treated with cisplatin and paclitaxel regimen for 4 courses during preoperative period and patients in control group were treated with same regimen during postoperative period.Results The total short-term effective rate of observation group was 75.0%, which was significantly higher than 52.5% in control group, the difference was statistically significant (P<0.05).The incidence of gastrointestinal reaction, myelo suppression and the total rate of toxicity in observation group was significantly lower than those of control group (P<0.05).Conclusions Compared with conventional postoperative chemotherapy, short-term effect of neoadjuvant chemotherapy is significant higher and has lower toxicity in treating advanced endometrial carcinoma, but further studies with larger sample size are still needed to define its value.